Oral isotretinoin for acne

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 11, 2018, Pages

  Costa, Caroline S ^a   Bagatin, Ediléia ^a   Martimbianco, Ana Luiza C ^b   da Silva, Edina M K ^a   Lúcio, Marília M ^a   Magin, Parker ^c   Riera, Rachel ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Brazilian Cochrane Centre   (Brazil)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; ANTIINFECTIVE AGENT; DERMATOLOGICAL AGENT;

ACNE; ACNE VULGARIS; CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; FOLLOW UP; HAIR LOSS; HUMAN; INFLAMMATION; MENTAL HEALTH; METHODOLOGY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; CHILD; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 85029200304     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009435.pub2     Document Type: Review

References (181)

1. Agarwal US. Randomization process, allocation concealment and blinding used in the trial [personal communication]. E mail to: C Costa 6 August 2013. 9495375
2. Agarwal US, Besarwal RK, Bhola K. Oral isotretinoin in different dose regimens for acne vulgaris: a randomized comparative trial. Indian Journal of Dermatology, Venereology and Leprology 2011;77(6):688-94. [CENTRAL: CN-00835026]9495374
3. Ahmad HM. Analysis of clinical efficacy, side effects, and laboratory changes among patients with acne vulgaris receiving single versus twice daily dose of oral isotretinoin. Dermatologic Therapy 2015;28(3):151-7. [CENTRAL: CN-01076629]9495377
4. Akman A, Durusoy C, Senturk M, Koc CK, Soyturk D, Alpsoy E. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Archives of Dermatological Research 2007;299(10):467-73. [CENTRAL: CN-00627669]9495379
5. Corlin R, Maas B, Mack-Hennes A. Oral administration of low doses of 13-cis-retinoic acid in acne papulopustulosa. Results of a multicenter study [13-cis-Retinsäure. Niedrig dosiert orale Anwendung bei Acne papulopustulosa]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete 1984;35(12):623-9. [CENTRAL: CN-00175184]9495381
6. Cumurcu T, Sezer E, Kilic R, Bulut Y. Comparison of dose-related ocular side effects during systemic isotretinoin administration. European Journal of Ophthalmology 2009;19(2):196-200. [CENTRAL: CN-00682992]9495383
7. De D, Kanwar AJ. Standard-dose isotretinoin vs. a combination of low-dose isotretinoin and azithromycin pulse in management of severe acne: preliminary report of a randomized study. British Journal of Dermatology 2011;165(Suppl 1):41. [CENTRAL: CN-00843694; EMBASE: 70479445]9495385
8. Dhaked RD, Meena RS, Maheshwari A, Agarwal US, Purohit S. A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris. Indian Dermatology Online Jounal 2016;7(5):378-85. [PUBMED: 27730033]9495387
9. Dhir R, Gehi NP, Agarwal R, More Y. Oral isotretinoin is as effective as a combination of oral isotretinoin and topical anti-acne agents in nodulocystic acne. Indian Journal of Dermatology, Venereology and Leprology 2008;74(2):187. [CENTRAL: CN-01093460]9495389
10. Faghihi G, Rakhsshanpour M, Abtahi-Naeini B, Nilforoushzadeh MA. The efficacy of 5% dapsone gel plus oral isotretinoin versus oral isotretinoin alone in acne vulgaris: a randomized double-blind study. Advanced Biomedical Research 2014;3:177. [PUBMED: 25250291]9495391
11. IRCT2014011015509N1 . Comparison of 5% dapsone gel plus oral isotretinoin with oral isotretinoin alone in young patients with moderate to severe facial acne. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2014011015509N1 (first received 7 April 2014). 9495392
12. Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum production and the clinical response in a multiple-dose trial. Journal of the American Academy of Dermatology 1980;3(6):602-11. [CENTRAL: CN-00333819]9495394
13. Goldstein JA, Pochi PE, Szott AS, Shalita AR, Thomsen RJ, Strauss JS. Comparative effect of isotretinoin and etretinate on sebaceous gland secretion and acne. Journal of Investigative Dermatology 1981;76(4):327-8. [CENTRAL: CN-00321299]9495396
14. Goldstein JA, Socha-Szott A, Thomsen RJ, Pochi PE, Shalita AR, Strauss JS. Comparative effect of isotretinoin and etretinate on acne and sebaceous gland secretion. Journal of the American Academy of Dermatology 1982;6 Suppl 4(Pt 2):760-5. [CENTRAL: CN-00365999]9495397
15. Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. European Journal of Dermatology 2001;11(6):538-44. [CENTRAL: CN-00375280]9495399
16. Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study of I3-cis-retinoic acid in acne vulgaris. British Journal of Dermatology 1983;108(3):333-43. [CENTRAL: CN-00030477]9495401
17. Jones DH, Forster RA, Mitchell J, Cunliffe WJ. A comparison of 13-cis-retinoic acid and erythromycin treatment in severe acne. British Journal of Dermatology 1983;109(Suppl 24):27-8. [CENTRAL: CN-00401430]9495403
18. Kapadia NF, Khalid G, Burhany T, Nakhoda T. Comparative efficacy and safety and efficacy of systemic 13-cis retinoic acid 20mg/day vs. 40mg/day in acne vulgaris. Journal of Pakistan Association of Dermatologists 2005;15(3):238-41. [CENTRAL: CN-01632170; EMBASE: 41820790]9495405
19. King K, Jones DH, Daltrey D, Cunliffe WJ. The effect of 13-cis retinoic acid on the skin microflora of patients with severe acne. Journal of Investigative Dermatology 1982;78(4):328. [CENTRAL: CN-00321308]9495407
20. King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. British Journal of Dermatology 1982;107(5):583-90. [CENTRAL: CN-00568857]9495408
21. Lee JW, Kim HK, Park MK, Yoo KH, Park KY, Li K, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Journal of Dermatology 2010;37(Suppl 1):132. [EMBASE: 70284853]9495410
22. Lee JW, Yoo KH, Park KY, Han TY, Li K, Seo SJ, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. British Journal of Dermatology 2011;164(6):1369-75. [CENTRAL: CN-00813000]9495411
23. Leheta T, El Garem Y, Abdel Hay R. Treatment of mild to moderate acne with three different modalities. British Journal of Dermatology 2011;165(Suppl 1):98. [CENTRAL: CN-00843838]9495413
24. Lester RS, Schachter GD, Light MJ. Isotretinoin and tetracycline in the management of severe nodulocystic acne. International Journal of Dermatology 1985;24(4):252-7. [CENTRAL: CN-00038541]9495415
25. Oprica C, Emtestam L, Hagstromer L, Nord CE. Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris. Acta Dermato-Venereologica 2007;87(3):246-54. [CENTRAL: CN-00589293]9495417
26. Peck GL, Olsen TG, Butkus D, Pandya M, Arnaud-Battandier J, Gross EG, et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. Journal of the American Academy of Dermatology 1982;6(4 Pt 2 Suppl):735-45. [CENTRAL: CN-00027541]9495419
27. Pigatto PD, Finzi AF, Altomare GF, Polenghi MM, Vergani C, Vigotti G. Isotretinoin versus minocycline in cystic acne: a study of lipid metabolism. Dermatologica 1986;172(3):154-9. [CENTRAL: CN-00303677]9495421
28. Prendiville JS, Logan RA, Russell Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clinical and Experimental Dermatology 1988;13(2):67-71. [CENTRAL: CN-00180614]9495423
29. ACTRN12612000062820 . Randomized, double-blind, placebo-controlled, parallel group clinical study of Isotretinoin 5 mg capsules (once daily) in the treatment of persistent low grade adult acne for 16 weeks followed by an open-label phase of 16 weeks - Protocol Number: ZPS- 365. www.anzctr.org.au/ACTRN12612000062820.aspx (first received 12 January 2012). 9495425
30. Cooney P. Isotretinoin ongoing trial [personal communication]. E mail to: C Costa 12 February 2013. 9495426
31. Rademaker M, Birchall N, Wishart J. Isotretinoin 5 mg/day for persistent adult acne. Australasian Journal of Dermatology 2013;54(Suppl 2):20. [CENTRAL: CN-01027222]9495427
32. Rademaker M, Birchall N, Wishart J. Isotretinoin 5mg/day in the treatment of persistent low grade adult acne. Therapy. 21st Congress of the European Academy of Dermatology and Venereology; 2012 Sep 27-30; Prague. Prague: European Academy of Dermatology and Venereology, 2012. 9495428
33. Rademaker M, Wishart JM, Birchall NM. Isotretinoin 5 mg daily for low-grade adult acne vulgaris - a placebo-controlled, randomized double-blind study. Journal of the European Academy of Dermatology and Venereology 2013;28(6):747-54. [CENTRAL: CN-00993404]9495429
34. Shetti SA, Nagesh HN, Hanumantharaya N. A randomized, open-label, comparative study of efficacy of low-dose continuous versus low-dose intermittent oral isotretinoin therapy in moderate-to-severe acne vulgaris. National Journal of Physiology, Pharmacy and Pharmacology 2017;7(9):941-6. [CENTRAL: CN-01417962]9495431
35. Shetti SKA, Nagabushan H, Harish MR. A study of low dose continuous versus low dose intermittent oral isotretinoin therapy in moderate to severe acne vulgaris. Indian Journal of Pharmacology 2013;45(Suppl 1):S80. [EMBASE: 71394541]9495432
36. Rapini RR, Konecky EA, Schillinger B, Comite H, Exner JH, Strauss JS, et al. Effect of varying dosages of isotretinoin on nodulocystic acne. Journal of Investigative Dermatology 1983;80(4):358. [CENTRAL: CN-00321214]9495434
37. Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, Comite H, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. Journal of the American Academy of Dermatology 1984;10(3):490-6. [CENTRAL: CN-00334209]9495435
38. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, et al. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. Journal of the American Academy of Dermatology 2001;45(2):187-95. [CENTRAL: CN-00349552]9495437
39. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. Journal of the American Academy of Dermatology 2001;45(2):196-207. [CENTRAL: CN-00349553]9495438
40. Tan J, Humphrey S, Lynde C, Vender R, Kerrouche N, Audibert F. Topical fixed-dose adapalene/benzoyl peroxide plus oral doxycycline: an evidence-based alternative to oral Isotretinoin in the treatment of severe nodular acne. Australasian Journal of Dermatology 2014;55:35-6. [CENTRAL: CN-01087981; EMBASE: 71820742]9495440
41. Tan J, Humphrey S, Vender R, Barankin B, Gooderham M, Kerrouche N, et al. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzolyl peroxide plus doxycycline vs. oral isotretinoin. British Journal of Dermatology 2014; Vol. 171, issue 6:1508-16. [CENTRAL: CN-01039302]9495441
42. Van der Meeren HL, Van der Schroeff JG, Stijnen T, Van Duren JA, Van der Dries HA, Van Voorst Vader PC. Dose-response relationship in isotretinoin therapy for conglobate acne. Dermatologica 1983;167(6):299-303. [CENTRAL: CN-00197666]9495443
43. Van der Schroeff JG, Van der Meeren HLM, Stijnen T, Van den Dries HAC, Van Duren JA, Van Voorst Vader PC. The treatment of acne conglobata using 13-cis-retinoic acid (isotretinoin) [De behandeling van acne conglobata met 13-cis vitamine A-zuur (isotretinoine)]. Nederlands Tijdschrift voor Geneeskunde 1983;127(41):1857-62. [CENTRAL: CN-00032666]9495444
44. Wahab MA, Rahman MH, Monamie NS, Jamaluddin M, Khondker L, Afroz W. Isotretinoin versus weekly pulse dose azithromycin in the treatment of acne - a comparative study. Journal of Pakistan Association of Dermatologists 2008;18(1):9-14. [CENTRAL: CN-00789353]9495446
45. Hoover KB, Miller CG, Galante NC, Langman CB. A double-blind, randomized, phase III, multicenter study in 358 pediatric subjects receiving isotretinoin therapy demonstrates no effect on pediatric bone mineral density. Osteoporosis International 2015;26(10):2441-7. [CENTRAL: CN-01258376]9495448
46. NCT00975143 . A double-blind, randomized, phase III, parallel group study evaluating the efficacy and safety of CIP-Isotretinoin in patients with severe recalcitrant nodular acne. clinicaltrials.gov/show/NCT00975143 (first received 11 September 2009). 9495449
47. Webster GF, Leyden JJ, Gross JA. Results of a phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne. Journal of Drugs in Dermatology 2014;13(6):665-70. [CENTRAL: CN-00995064; PUBMED: 24918555]9495450
48. Herane MI, Fuenzalida H, Zegpi E, De Pablo C, Espadas MJ, Trullás C, et al. Specific gel-cream as adjuvant to oral isotretinoin improved hydration and prevented TEWL increase - a double-blind, randomized, placebo-controlled study. Journal of Cosmetic Dermatology 2009;8(3):181-5. [CENTRAL: CN-00728527]9495452
49. Kus S, Gun D, Demirçay Z. Vitamin E does not reduce the side-effects of isotretinoin in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology 2002;16(Suppl 1):126. [CENTRAL: CN-00416083]9495455
50. Kus S, Gun D, Demirçay Z, Sur H. Vitamin E does not reduce the side-effects of isotretinoin in the treatment of acne vulgaris. International Journal of Dermatology 2005;44(3):248-51. [CENTRAL: CN-00515160; EMBASE: 2005143042]9495454
51. Li B, Geng L, Xu WB, Zhang M, Zhou M. Effects of Qingfei Liangxue Fa on sebum excretion rate and free fatty acid of patients with acne vulgaris. Zhongguo Linchuang Kangfu [Chinese Journal of Clinical Rehabilitation] 2004;8(20):4056-7. [CENTRAL: CN-00508753]9495457
52. Lin J, Shih I, Yu C. Hemodialysis-related nodulocystic acne treated with isotretinoin. Nephron 1999;81(2):146-50. [CENTRAL: CN-00159587]9495459
53. Liu CZ, Lei B, Zheng JF. Randomized control study on the treatment of 26 cases of acne conglobata with encircling acupuncture combined with venesection and cupping. Zhen Ci Yan Jiu [Acupuncture Research] 2008;33(6):406-8. [CENTRAL: CN-00681580]9495461
54. Shen D, Xu X. A randomised controlled trial of compound shecao decoction versus Isotretinoin in the treatment of acne vulgaris. Journal of Clinical Dermatology 2000;29(4):201-3. [CENTRAL: CN-00454654]9495463
55. Strauss JS, Gottlieb AB, Jones T, Koo JY, Leyden JJ, Lucky A, et al. Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris: a randomized trial. Journal of the American Academy of Dermatology 2000;43(5 Pt 1):777-84. [CENTRAL: CN-00328297]9495465
56. Sun HX, Yang W. 33 cases of severe acne treated by capsulae isotretinoin (Tai Ersi treatment). Chinese Journal of Leprosy and Skin Diseases 2000;16(4):273. [CENTRAL: CN-00454697]9495467
57. Williams RE, Doherty VR, Perkins W, Aitchison TC, Mackie RM. Staphylococcus aureus and intra-nasal mupirocin in patients receiving isotretinoin for acne. British Journal of Dermatology 1992;126(4):362-6. [CENTRAL: CN-00083552]9495469
58. Faghihi G, Mokhtari F, Fard NM, Motamedi N, Hosseini SM. Comparing the efficacy of low dose and conventional dose of oral isotretinoin in treatment of moderate and severe acne vulgaris. Journal of Research in Pharmacy Practice 2017;6(4):233-8. [PUBMED: 29417084]9495471
59. IRCT201104094310N6 . Comparison of therapeutic effects of oral erythromycin along with low dose oral isotretinoin and oral erythromycin and low dose flutamide versus doxycyclin in female severe acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201104094310N6 (first received 19 April 2014). 9495473
60. IRCT2013110315246N1 . Acne cure rate in patients hyperandrogenism with two drugs of decuttane and cyproterone compound [Comparison of therapiotic effects of oral flutamide and cyproteron compound on female moderate acne]. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2013110315246N1 (first received 14 December 2013). 9495475
61. Acne Core Outcomes Research Network (ACORN). sites.psu.edu/acnecoreoutcomes/ (accessed 16 October 2016).
62. Adityan B, Kumari R, Thappa DM. Scoring systems in acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology 2009;75(3):323-6. [PUBMED: 19439902]
63. Aksu AEK, Metintas S, Saracoglu ZN, Gurel G, Sabuncu I, Arikan I, et al. Acne: prevalence and relationship with dietary habits in Eskisehir, Turkey. Journal of the European Academy of Dermatology and Venereology 2012;26(12):1503-9. [PUBMED: 22070422]
64. Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, Shear NH, Dormuth CR, et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. Journal of Investigative Dermatology 2013;133(4):907-12. [PUBMED: 23096714]
65. Amado JM, Matos ME, Abreu AM, Loureiro L, Oliveira J, Verde A, et al. The prevalence of acne in the north of Portugal. Journal of the European Academy of Dermatology and Venereology 2006;20(10):1287-95. [PUBMED: 17062047]
66. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD004425.pub6]
67. Augustin MI, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I. Prevalence of skin lesions and need for treatment in a cohort of 90, 880 workers. British Journal of Dermatology 2011;165(4):865-73. [PUBMED: 21623753]
68. Azoulay L, Blais L, Koren G, LeLorier J, Berard A. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. Journal of Clinical Psychiatry 2008;69(4):526-32. [PUBMED: 18363422]
69. Ballanger F, Baudry P, N'Guyen JM, Khammari A, Dréno B. Heredity: a prognostic factor for acne. Dermatology 2006;212(2):145-9. [PUBMED: 16484821]
70. Barbaric J, Abbott R, Posadzki P, Car M, Gunn LH, Layton AM, et al. Light therapies for acne. Cochrane Database of Systematic Reviews 2016, Issue 9. [DOI: 10.1002/14651858.CD007917.pub2]
71. Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. Journal of Affective Disorders 2001;66(2-3):159-64. [PUBMED: 11578668]
72. Bernstein CN, Nugent Z, Longobardi T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. American Journal of Gastroenterology 2009;104(11):2774-8. [PUBMED: 19623167]
73. Binder DK, Horton JC, Lawton MT, McDermott MW. Idiopathic intracranial hypertension. Neurosurgery 2004;54(3):538-51. [PUBMED: 15028127]
74. Brokelman RB, Haverkamp D, Van Loon C, Hol A, Van Kampen A, Veth R. The validation of the visual analogue scale for patient satisfaction after total hip arthroplasty. European Orthopaedics and Traumatology 2012;3(2):101-5. [PUBMED: 22798966]
75. Burke BM, Cunliffe WJ. The assessment of acne vulgaris - the Leeds technique. British Jounal of Dermatology 1984;111(1):83-92. [PUBMED: 6234917]
76. Burton JL, Cunliffe WJ, Stafford I, Shuster S. The prevalence of acne vulgaris in adolescence. British Journal of Dermatology 1971;85(2):119-26. [PUBMED: 4255129]
77. Bérard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. British Journal of Clinical Pharmacology 2007;63(2):196-205. [PUBMED: 17214828]
78. Cao H, Yang G, Wang Y, Liu JP, Smith CA, Luo H, et al. Complementary therapies for acne vulgaris. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD009436.pub2]
79. Cheng CE, Irwin B, Mauriello D, Liang L, Pappert A, Kimball AB. Self-reported acne severity, treatment, and belief patterns across multiple racial and ethnic groups in adolescent students. Pediatric Dermatology 2010;27(5):446-52. [PUBMED: 20796234]
80. Chia CY, Lane W, Chibnall J, Allen A, Siegfried E. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Archives of Dermatology 2005;141(5):557-60. [PUBMED: 15897376 ]
81. Clark SM, Cunliffe WJ. Acne flare and isotretinoin - incidence and treatment. British Journal of Dermatology 1995;133(Suppl 45):26.
82. Coates P, Adams CA, Cunliffe WJ, McGinley KT, Eady EA, Leyden JJ, et al. Does oral isotretinoin prevent propionibacterium acnes resistance?. Dermatology 1997;195(Suppl 1):4-9. [PUBMED: 9310739]
83. Cohen J, Adams S, Patten S. No association found between patients receiving isotretinoin for acne and the development of depression in a Canadian prospective cohort. Canadian Journal of Clinical Pharmacology 2007;14(2):e227-33. [PUBMED: 17556790]
84. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. Journal of Clinical Pharmacology 1983;23(11-12):534-9. [PUBMED: 6582073]
85. Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, et al. The prevalence of acne in adults 20 years and older. Journal of the American Academy of Dermatology 2008;58(1):56-9. [PUBMED: 17945383]
86. Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. American Journal of Gastroenterology 2010;105(9):1986-93. [PUBMED: 20354506]
87. Cunliffe WJ, Shuster S. The rate of sebum excretion in man. British Journal of Dermatology 1969;81(9):697-704. [PUBMED: 4243403]
88. Cunliffe WJ, Williams SM, Tan SG. Sebum excretion rate investigations. A new absorbent paper. British Journal of Dermatology 1975;93(3):347. [PUBMED: 1191540]
89. Cunliffe WJ. Acne. Update Postgraduate Centre Series. Petersfield: Update Publications Ltd, 1981.
90. Cunliffe WJ, Van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997;194(4):351-7. [PUBMED: 9252756]
91. Cunliffe WJ, Meynadier J, Alirezai M, George SA, Coutts I, Roseeuw DI, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. Journal of the American Academy of Dermatology 2003;49(3 Suppl):S218-26.
92. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. Journal of the American Academy of Dermatology 1992;26(4):509-606. [PUBMED: 1597546]
93. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2002;21(11):1575-600.
94. Del Rosso JQ. Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses. Journal of Clinical and Aesthetic Dermatology 2012;5(11):17-24. [PUBMED: 23198008]
95. Demircay Z, Kus S, Sur H. Predictive factors for acne flare during isotretinoin treatment. European Journal of Dermatology 2008;18(4):452-6. [PUBMED: 18573721]
96. Dispenza MC, Wolpert EB, Gilliland KL, Dai P, Cong Z, Nelson AM, Thiboutot DM. Systemic isotretinoin therapy normalizes exaggerated TLR-2- mediated innate immune responses in acne patients. Journal of Investigative Dermatology 2012;132(9):2198-205. [PUBMED: 22513780]
97. Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. International Journal of Dermatology 1997;36(6):416-8. [PUBMED: 9248884]
98. Downing DT. Photodensitometry in the thin-layer chromatographic analysis of neutral lipids. Journal of Chromatography 1968;38(1):91-9. [PUBMED: 5688076]
99. UK Database of Uncertainties about the Effects of Treatments (DUETs). What are the long-term effects of taking isotretinoin for acne? In particular, if it raises cholesterol so significantly during the course of treatment, is there any evidence to show future problems linked to this?. www.library.nhs.uk/duets/ViewResource.aspx?resID=302864&tabID=294 (accessed 23 March 2014).
100. UK Database of Uncertainties about the Effects of Treatments (DUETs). Early intervention with oral isotretinoin versus alternative treatments for moderate or mild acne. www.library.nhs.uk/duets/ViewResource.aspx?resID=321332&tabID=296 (accessed 23 March 2014).
101. UK Database of Uncertainties about the Effects of Treatments (DUETs). Is there a causative association between oral isotretinoin and depression and suicidal behaviour in acne patients?. www.library.nhs.uk/duets/ViewResource.aspx?resID=321407&tabID=297 (accessed 23 March 2014).
102. UK Database of Uncertainties about the Effects of Treatments (DUETs). Low dose versus standard dose isotretinoin for acne. www.library.nhs.uk/duets/ViewResource.aspx?resID=407423&tabID=297 (accessed 23 March 2014).
103. Engels EA, Schmid CH, Terrin N, Olkin I, Lau J. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Statistics in Medicine 2000;19(13):1707-28.
104. Etminan M, Bird ST, Delaney JA, Bressler B, Brophy JM. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatology 2013;149(2):216-20. [PUBMED: 23426479]
105. Falcon RH, Lee WL, Shalita AR, Suntharalingam K, Fikrig SM. In vitro effect of isotretinoin on monocyte chemotaxis. Journal of Investigative Dermatology 1986;86(5):550-2. [PUBMED: 3462263]
106. Ferahbas A, Turan MT, Esel E, Utas S, Kutlugun C, Kilic CG. A pilot study evaluating anxiety and depressive scores in acne patients treated with isotretinoin. Journal of Dermatological Treatment 2004;15(3):153-7. [PUBMED: 15204147]
107. Finlay AY, Khan GK. Dermatology life quality index (DLQI) - a simple practical measure for routine clinical use. Clinical and Experimental Dermatology 1994;19(3):210-6. [PUBMED: 8033378]
108. Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD002086.pub2]
109. Ghodsi ZS, Orawa H, Zouboulis CC. Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study. Journal of the European Academy of Dermatology and Venereology 2009;129(9):2136-41. [PUBMED: 19282841]
110. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs 2003;63(15):1579-96. [PUBMED: 12887264]
111. Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti C, et al. A consensus-based practical and daily guide for the treatment of acne patients. Journal of the European Academy of Dermatology and Venereology 2016;30(9):1480-90. [PUBMED: 27177989]
112. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. Journal of the American Academy of Dermatology 1999;41(4):577-80. [PUBMED: 10495379]
113. GRADE Working Group, McMaster University. GRADEpro GDT. Version (accessed prior to 1 November 2018). Hamilton (ON): GRADE Working Group, McMaster University, 2014.
114. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380-2. [PUBMED: 21185693]
115. Halvorsen JA, Stern RS, Dalgard F, Thoresen M, Bjertness E, Lien L. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. Journal of Investigative Dermatology 2011;131(2):363-70. [PUBMED: 20844551]
116. Harms M, Masouyé I, Radeff B. The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica 1986;172(3):148-53. [PUBMED: 2938992]
117. Hazen PG, Carney JF, Walker AE, Stewart JJ. Depression - a side effect of 13-cis-retinoic acid therapy. Journal of the American Academy of Dermatology 1983;9(2):278-9. [PUBMED: 6577039]
118. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60. [PUBMED: 12958120]
119. Higgins JP, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
120. Holland DB, Jeremy AH, Roberts SG, Seukeran DC, Layton AM, Cunliffe WJ. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. British Journal of Dermatology 2004;150(1):72-81. [PUBMED: 14746619]
121. Hull PR, Demkiw-Bartel C. Isotretinoin use in acne: prospective evaluation of adverse events. Journal of Cutaneous Medicine & Surgery 2000;4(2):66-70. [PUBMED: 11179927]
122. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8. [PUBMED: 15545678]
123. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Archives of Dermatology 2000;136(10):1231-6. [PUBMED: 11030769]
124. Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study of I3-cis-retinoic acid in acne vulgaris. British Journal of Dermatology 1983;108(3):333-43. [PUBMED: 6219690]
125. Karimkhani C, Dellavale RP, Coffeng LE, Flohr C, Hay RJ, Langan SM, et al. Global skin disease morbidity and mortality: an update from the Global Burden of Disease Study 2013. JAMA Dermatology 2017;153(5):406-12.
126. Katsambas AD, Cunliffe WJ, Zouboulis CC. Clinical aspects of acne vulgaris. In: Zouboulis CC, Katsambas AD, Kligman AM editor(s). Pathogenesis and Treatment of Acne and Rosacea. 1. Berlin Heidelberg: Springer-Verlag, 2014:213-22.
127. Kaymak Y, Taner E, Taner Y. Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents. International Journal of Dermatology 2009;48(1):41-6. [PUBMED: 19126049]
128. Kilkenny M, Merlin K, Plunkett A, Marks R. The prevalence of common skin conditions in Australian school students: 3. acne vulgaris. British Journal of Dermatology 1998;139(5):840-5. [PUBMED: 9892951]
129. Kim J. Review of the innate immune response in acne vulgaris: activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology 2005;211(3):193-8. [PUBMED: 16205063]
130. Kontaxakis VP, Skourides D, Ferentinos P, Havaki-Kontaxaki BJ, Papadimitriou GN. Isotretinoin and psychopathology: a review. Annals of General Psychiatry 2009;8(2):1-8. [PUBMED: 19154613]
131. Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, et al. New developments in our understanding of acne pathogenesis and treatment. Experimental Dermatology 2009;18(10):821-32. [PUBMED: 19555434]
132. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. New England Journal of Medicine 1985;313(14):837-41. [PUBMED: 3162101]
133. Layton A. The use of isotretinoin in acne. Dermato-Endocrinology 2009;1(3):162-9. [PUBMED: 20436884]
134. Layton AM. Disorders of sebaceous glands. In: Burns T, Breathnach S, Cox N, Griffiths C editor(s). Rook's Textbook of Dermatology. 8th Edition. Vol. 2, Oxford: Blackwell Publishing, 2010:38-66.
135. Lee SY, Jamal MM, Nguyen ET, Bechtold ML, Nguyen DL. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. European Journal of Gastroenterology & Hepatology 2016;28(2):210-6. [PUBMED: 26545085]
136. Lehmann HP, Andrews JS, Robinson KA, Holloway VL, Goodman SN. Management of acne. www.ncbi.nlm.nih.gov/books/NBK33218/ (accessed prior to 9 November 2018). [PUBMED: 11898669]
137. Lehucher-Ceyrac D, De La Salmoniere P, Chastang C, Morel P. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999;198(3):278-83. [PUBMED: 10393453]
138. Leyden JJ, Del Rosso JQ, Baum EW. The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. Journal of Clinical and Aesthetic Dermatology 2014;7(2 Suppl):S3-21. [PUBMED: 24688620]
139. Lidén S, Goc¨ransson K, Odsell L. Clinical evaluation in acne. Acta Dermato-Venereologica 1980;Suppl 89:47-52.
140. Magin P, Pond D, Smith W. Isotretinoin, depression and suicide: a review of the evidence. British Journal of General Practice 2005;55(511):134-8. [PUBMED: 15720936]
141. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. British Journal of Dermatology 1999;140(4):672-6. [PUBMED: 10233319]
142. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Seminars in Cutaneous Medicine and Surgery 2005;24(2):92-102. [PUBMED: 16092797]
143. McGrath EJ, Lovell CR, Gillison F, Darvay A, Hickey JR, Skevington SM. A prospective trial of the effects of isotretinoin on quality of life and depressive symptoms. British Journal of Dermatology 2010;163(6):1323-9. [PUBMED: 21137117]
144. International Council for Harmonisation (ICH). MedDra (Medical Dictionary for Regulatory Activities Terminology). www.meddra.org (accessed 16 October 2016).
145. Miles AA, Misra SS. The estimation of the bacteriocidal power of blood. Journal of Hygiene 1938;38(6):732. [PUBMED: 20475467]
146. Min S, Kong HJ, Yoon C, Kim HC, Suh DH. Development and evaluation of an automatic acne lesion detection program using digital image processing. Skin Research and Technology 2013;19(1):e423-32.
147. Nast A, Bayerl C, Borelli C, Degitz K, Dirschka T, Erdmann R, et al. S2k - Guideline on the therapy of acne. Journal of the German Society of Dermatology 2010;379(9813):361-72.
148. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermato-Endocrinology 2009;1(3):177-87. [PUBMED: 20436886]
149. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Isotretinoin temporally regulates distinct sets of genes in patient skin. Journal of Investigative Dermatology 2009;129(4):1038-42. [PUBMED: 18987667]
150. Ng CH, Tam MM, Celi E, Tate B, Schweitzer I. Prospective study of depressive symptoms and quality of life in acne vulgaris patients treated with isotretinoin compared to antibiotic and topical therapy. Australasian Journal of Dermatology 2002;43(4):262-8. [PUBMED: 12423432]
151. Plewig G, Kligman AM. Acne and Rosacea. 3rd Edition. Berlin Heidelberg: Springer-Verlag, 2000.
152. Pochi PE, Shalita AR, Strauss JS, Webster SB, Cunliffe WJ, Katz HI, et al. Report of the consensus conference on acne classification. Journal of the American Academy of Dermatology 1991;24(3):495-500. [PUBMED: 1829466]
153. Racine A, Cuerq A, Bijon A, Ricordeau P, Weill A, Allemand H, et al. Isotretinoin and risk of inflammatory bowel disease: a French nationwide study. American Journal of Gastroenterology 2014;109(4):563-9. [PUBMED: 24535094]
154. Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?. Australasian Journal of Dermatology 2013;54(3):157-62. [PUBMED: 23013115]
155. Rashtak S, Khaleghi S, Pittelkow MR, Larson JJ, Lahr BD, Murray JA. Isotretinoin exposure and risk of inflammatory bowel disease. JAMA Dermatology 2014;150(12):1322-6. [PUBMED: 25207875]
156. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
157. Rocha MA, Costa CS, Bagatin E. Acne vulgaris: an inflammatory disease even before the onset of clinical lesions. Inflammation & Allergy Drug Targets 2014;13(3):162-7. [PUBMED: 24909146]
158. SBD (Sociedade Brasileira de Dermatologia). Nosologic profile of dermatologic visits in Brazil [Perfil nosológico das consultas dermatológicas no Brasil]. Anais Brasileiro de Dermatologia 2006;81(6):545-54.
159. Schaefer C, Meister R, Weber-Schoendorfer C. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Archives of Gynecology and Obstetrics 2010;281(2):221-7. [PUBMED: 19444462]
160. Schmitt J, Deckert S, Alam M, Apfelbacher C, Barbaric J, Bauer A, et al. Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN). British Journal of Dermatology 2016;174(2):287-95. [PUBMED: 26779929]
161. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet 2002;359(9307):696-700. [PUBMED: 11879884]
162. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel groups randomised trials. Journal of Clinical Epidemiology 2010;63(8):834-40. [PUBMED: 20346629]
163. Shen Y, Wang T, Zhou C, Wang X, Ding X, Tian S, et al. Prevalence of acne vulgaris in Chinese adolescents and adults: a community-based study of 17, 345 subjects in six cities. Acta Dermato-Venereologica 2012;92(1):40-4. [PUBMED: 21710106]
164. Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin. Archives of Dermatology 2007;143(9):1187-8. [PUBMED: 17875883]
165. Stern RS. Dermatologists and office-based care of dermatologic disease in the 21st century. Journal of Investigative Dermatology Symposium Proceedings 2004;9(2):126-30. [PUBMED: 15083778]
166. Strauss JS, Pochi PE. The quantitative gravimetric determination of sebum production. Journal of Investigative Dermatology 1961;36:293-8.
167. Sundstrom A, Alfredsson L, Sjolin-Forsberg G, Gerden B, Bergman U, Jokinen J. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010;341:c5812. [PUBMED: 21071484]
168. Tan HH, Tan AW, Barkham T, Yan XY, Zhu M. Community-based study of acne vulgaris in adolescents in Singapore. British Journal of Dermatology 2007;157(3):547-51. [PUBMED: 17655737]
169. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. Journal of the American Academy of Dermatology 2009;60(5 Suppl):S1-50. [PUBMED: 19376456 ]
170. Turner L, Savovic J, Higgins J, Reeves B, Sterne J, et al. Methods Innovation Fund updates: the Cochrane Risk of Bias tool extension for non-randomized studies and studies of non-parallel design. Cochrane Methods 2013;Suppl 1:1-58.
171. Uslu G, Sendur N, Uslu M, Savk E, Karaman G, Eskin M. Acne: prevalence, perceptions and effects on psychological health among adolescents in Aydin, Turkey. Journal of the European Academy of Dermatology and Venereology 2008;22(4):462-9. [PUBMED: 18179519]
172. Webster GF, Leyden JJ, Gross JA. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. Journal of the American Academy of Dermatology 2013;69(5):762-7. [PUBMED: 23953888]
173. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet 2012;379(9813):361-72. [PUBMED: 21880356]
174. Williamson P, Kligman AM. A new method for the quantitative investigation of cutaneous bacteria. Journal of Investigative Dermatology 1965;45(6):498-503. [PUBMED: 5321315]
175. Yazici K, Baz K, Yazici AE, Köktürk A, Tot S, Demirseren D, et al. Disease-specific quality of life is associated with anxiety and depression in patients with acne. Journal of the European Academy of Dermatology and Venereology 2004;18(4):435-9. [PUBMED: 15196157]
176. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology 2016;74(5):945-73. [PUBMED: 26897386]
177. Zeichner JA. Inflammatory acne treatment: review of current and new topical therapeutic options. Journal of Drugs in Dermatology 2016;15(1 Suppl 1):s11-6. [PUBMED: 26741391]
178. Medicis, the Dermatology Company. Prescribing Information. pi.medicis.us/ziana.pdf (accessed 7 October 2014).
179. Zomerdijk IM, Ruiter R, Houweling LM, Herings RM, Sturkenbonn MC, Straus SM, et al. Isotretinoin exposure during pregnancy: a population-based study in The Netherlands. BMJ Open 2014;4(11):e005602. [PUBMED: 25392022]
180. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003;206(1):37-53. [PUBMED: 12566804]
181. Costa CS, Bagatin E, da Silva EMK, Lúcio MM, Magin P, Riera R. Oral isotretinoin for acne. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD009435]